CytoDyn Doses First Patient in Phase 2a Alzheimer’s Trial of Leronlimab
VANCOUVER, Wash., June 11, 2026 CytoDyn Inc. announced that the first patient has been dosed in the Phase 2a...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
VANCOUVER, Wash., June 11, 2026 CytoDyn Inc. announced that the first patient has been dosed in the Phase 2a...
